medigraphic.com
ISSN 1817-5996 (Electronic)

2017, Number 2

<< Back Next >>

Rev Cub de Reu 2017; 19 (2)

Survival in patients with Systemic Sclerosis at Holguín's Province

Remedios BSE, Rivas CR, Montada CE, del Campo AE, Pérez TL, Caselles FHL

Language: Spanish
References: 37
Page: 65-72
PDF size: 360.71 Kb.


ABSTRACT

Introduction: we must go on board when the theme am about the survival in patients with Systemic Sclerosis than in spite of the compared improvement another decades, still you relate with a considerable decrease of survival, these published studies are important because they help to document any change in the natural history of the disease and more relevant still, the effects of new medical treatments.
Objectives: determining the patients' rates of survival with, identifying the cause of death, and evaluating the association of clinical, laboratory variables with survival establishing a predictive value.
Method: start accomplished a study of series of cases itself March of the 2015-2016, you included 44 patients. A data base utilized itself that SPSS processed according to statistical parcel 15.0 himself, it applied Liked Chi's Test itself, the significance determined in p= 0.05 itself. They determined the rates of survival of the cases, represented in a curve Kaplan Meier. You utilized Cox's model for the evaluation of the influence of independent variables on the survival of this analysis, survival, Cox's logistic regression, for predictors selected the ones that were statistically significant to conform indicating correlated prognosis’s themselves prognosises.
Results: the survival once the 5 10 and 15 years was accumulated after the diagnosis went from 95 %, 88 % and 77 % respectively. You cause them of more frequent death; renal insufficiency and infections with five patients each for a 35.7 %. Dyspnea (p= 0.00), the leucopenia (p=0.00) and the proteinuria 0.5 g 24 (p 0.02) correlate to a minor survival h. The predictor of mortality revealed significant association courageously in the multivariate analysis the positive electrocardiogram, fundamentally arrhythmias (p= 0.03).
Findings: the survival of the disease diminishes as you advance in the time, related with factors of bad prognosis like dyspnea, leucopenia and proteinuria, being the arrhythmias in the electrocardiogram, predictor of mortality.


REFERENCES

  1. Simeón CP, Fonollosa V, Vilardell M. Epidemiología y clasificación de la esclerosis sistémica (esclerodermia). En Avances es esclerosis sistémica (esclerodermia). Barcelona: Ed. Marge Médica Books; 2009:21-40.

  2. Fonollosa V, Simeón CP, Vilardell M. La vasculopatía esclerodérmica: de la lesión vascular a la fibrosis. En Avances es esclerosis sistémica (esclerodermia). Barcelona: Ed. Marge Médica Books; 2009:55-70

  3. Cutolo M, Grassi W, MatucciCerinic M. Raynaud's phenomenon and the role of capillaroscopy. Artritis Rheum. 2003;48(3):23-30.

  4. Ingegnoli F, Boracchi P, Gualtierotti R, Lubatti C, Meani L, Zahalkova L, et al. Prognostic model based on nail fold capillaroscopy for identifying Raynaud's phenomenon patients at high risk for the development of a scleroderma spectrum disorder. Arthritis Rheum. 2008;58(2):174-82.

  5. Koening M, Joyal F, Fritzler J. et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis. Arthritis Rheum.2008; 58:3.902-912.

  6. Steen VD. The many faces of scleroderma. Rheum Dis Clin N Am. 2008;34:115.

  7. Krieg T, Takehara K. Skin disease: a cardinal feature of systemic sclerosis. Rheumatology. 2009;48(sup 3): iii14-18.

  8. Fonollosa V, Simeón CP, Vilardell M. Fenómeno de Raynaud en la esclerodermia: algo más que un vasospasmo. Med Clin.2008;9:24-7.

  9. Hachulla E, Clerson P, Launay D, et al. Natural history of ischemic digital ulcers in systemic sclerosis: single-center retrospective longitudinal study. J. Rheumatol. 2007;34(2):423-30.

  10. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology. 2009;48(sup 3): iii19-24.

  11. Brito-Zerón P, Sisó-Almirall A, Bové-Boa-da A, Ramos-Casals M. Diagnóstico y tratamiento de la enfermedad vascular periférica en la esclerosis sistémica (esclerodermia). En Avances esclerosis sistémica (esclerodermia). Barcelona: Ed. Marge Médica Books. 2009;87-102.

  12. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology. 2009;48(sup 3): iii36-39.

  13. McLaughlin V, Humbert M, Coghlan G, Nash P, Steen V. pulmonary arterial hypertension: the most devastating vascular complicating of systemic sclerosis. Rheumatology. 2009;48(sup 3): iii25 -31

  14. Callejas Rubio JL, Moreno Escobar E, Martin de la Fuente, Ortego Centeno N. Hipertensión arterial pulmonar en la esclerosis sistémica (esclerodermia). En Avances es esclerosis sistémica (esclerodermia). Barcelona: Ed. Marge Médica Books; 2009:117-36

  15. Sánchez Román J, Castillo Palma MJ, García Hernández FJ. Enfermedad pulmonar intersticial en la esclerosis sistémica (esclerodermia). En Avances es esclerosis sistémica (esclerodermia). Barcelona: Ed. MargeMedícaBooks; 2009:137-58.

  16. Llerena Reyes G, Guibert Toledano M, López Cabreja G.et al.Esclerosis sistémica. Evaluación clínico-epidemiológica de una serie de casos en dos centros de referencia en Cuba.[Internet]. 2014 [cited 2016 March 23]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/366/html_1

  17. Remedios Batista SE. Mortalidad y principales causas de muerte en pacientes afectados por Esclerosis Sistémica en la Provincia de Santiago de Cuba (1995-2001). (Tesis). Santiago de Cuba. Hospital Provincial Saturnino Lora; 2002.

  18. Martínez AH, Llerena GAR. Medición de actividad lúpica en pacientes portadores de lupus eritematoso sistémico (LES). Rev Cubana de Reumatol. 2000;2(1).

  19. Molinero Rodríguez C, Prada Hernández D, López Aguilera IR, Gómez Morejón JA. Impacto laboral por enfermedades reumáticas en el municipio 10 de octubre. Rev Cubana de Reumatol[ Internet]. 2003 [citado 2017 feb 12];3(1):[aprox. 8 p.]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/156

  20. Pérez Campos D, Estevez Del Toro M, Peña Casanovas A, González Rojas PP, Morales Sánchez L, Gutiérrez Rojas AR. Are high doses of prednisone necessary for treatment of interstitial lung disease in systemic sclerosis? Rheumat .Clin.[Internet]. 2012 Mar-Apr; [cited 2016 March 23]8(2):58-62. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed?

  21. López Mantecón AM, Hernández Cuellar MI, Prada Hernández DM, Molinero Rodríguez C, Reyes Pineda Y. Esclerosis sistémica y embarazo. Revista Cubana de Reumatol [rInternet]. 2013 [citado 2017 Ene 12];15(2):[aprox. 6 p.]. Disponible en: http://www.revreumatologia.sld.cu/index.php/reumatologia/article/view/207

  22. Alarcón de Segovia. Tratado Hispanoamericano de Reumatología. Vol. II. Cap. 73 ed. en español, Bogotá: Ed. Nomos SA; 2006: 887-909.

  23. Fériz AR, Louis MR, Espinoza RL, Khamashta M, Cerinic MM, Sanmartí R, et al. Enfermedades inflamatorias reumatológicas. Cap. 18, ed. PANLAR. 2016:397-419.

  24. Valentini G, Vettori S, Cuomo G, Iudici M, D'Abrosca V, Capocotta D, et. al. Early Systemic Sclerosis: short- term disease evolution and factor predicting the development of new manifestations of organ involvement. Arthritis Research & Therapy [Internet]. 2012.[cited 2016 March 23] 14(4):118. Disponible en: http://arthritis-research.com/content/14/4/R188.

  25. Walker KM, Pope J. participating members of the Scleroderma Clinical Trials Consortium (SCTC); Canadian Scleroderma Research Group (CSRG).Treatment of Systemic Sclerosis Complications: What to Use When First-Line Treatment Fails-A Consensus of Systemic Sclerosis Experts. Semin Arthritis Rheum.[Internet]. 2012 Mar 29.[Cited 2016 March 23]. Disponible en:http://linkinghub.elsevier.com/retrieve/pii/

  26. Dimitroulas T, Giannakoulas G, Karvounis H, Settas L, KitasGD.Systemic sclerosis-related pulmonary hypertension: unique characteristics and future treatment targets,Curr Pharm Des.[Internet].2012 Apr 1. [Cited 2016 March 23];18(11):1457-64. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed

  27. Chan PT, Mok CC. Pauci -immune crescentic glomerulonephritis in limited cutaneous systemic sclerosis. [Internet]. 2012 Aug; 31. [Cited 2016 Mar 23](8):1273-7. Disponible en: http://dx.doi.org/10.1007/s10067-012-2010-8.

  28. Furst DE, Tseng CH, Clements PJ, Strange C, Tashkin DP, et al. Scleroderma Lung Study. Adverse events during the Scleroderma Lung Study. Am J Med. 2011;124(5):459-67.

  29. Ling TC, Jhonston BT. Esofhageal investigations in connective tissue disease: whichs tests are most appropriate. North Island.Jan. 2001:33-6.

  30. Revielle JD, Fischbach M, Mc. Nearney T Systemic Sclerosis in 3 U.S. Ethnic groups: Serologic, and inmunoeneologic determinants. Semin Arthritis rheum. 2001;30(5):332-446.

  31. Madelon C Vonk, Frank H J van den Hoogen, Piet L C M van Riel, Gabriele Valentini. What does the clinician need to improve patient care in systemic sclerosis? Validated clinimetric criteria, useful in the early phase of systemicarelacking. Ann Rheum Dis [Internet]. 2007.[Cited 2016 March 23] 66:1129-31. Disponible en: www.annrheumdis.com

  32. Domsic F, Rodríguez-Reyna T, Kuwuana M, Noreen Lucas M, Thomas A, et al. Anti–U11/U12 RNP Antibodies in Systemic Sclerosis: A New Serologic Marker Associated With Pulmonary Fibrosis. Arthritis &Rheumat 2009;61(7):958-65.

  33. Valentini G, Romano MF, Naclerio C, Bisogni R, Lamberti A, Turco MC, et al. Increased expression of CD40 ligand in activated CD4+ T lymphocytes of systemic sclerosis patients. J Autoimmun. 2000 Aug;15(1):61-6.

  34. Nelson JL. Microchimerism and scleroderma. Program in Human Inmunogenetics, Fred Hutchinson Cancer Rearch Center, and Rheumatology, Seattle. 1999:15-21.

  35. Herrick AL, Van dnHoogen F, Gabrielli A, Tamimi N, Reid C, O'connell D, et al. PModified- reléase Sildenafil reduces Raynaud’s phenomenon attack frequency in the limited cutaneous Systemic Sclerosis. Arthritis Rheum. 2011;63(3):775-82.

  36. Sakurai K, Otsuka A, Miyachi Y, Kabashima K. Fixed drug eruption induced by Cyclophosphamide, Eur J Dermatol.[Serial on internet]. 2012 May-Jun; 22 [Cited 2016 March 23] (3):401-2. Disponible en: http://www.jle.com/medline, md?

  37. Calguneri M, Apras S, Ozbalkan Z, Ertenli I, Kiraz S, Ozturk MA, CelikI.The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis.[Internet]. 2003 Oct;[Cited 2016 March 23] 22(4-5):289-94. Disponible en: http://dx.doi.org/10.1007/s10067-003-0733-2




2020     |     www.medigraphic.com